Table 1.

Group differences at baseline

	Risperidone (N=18)	Placebo (N=22)	p-value
Age (Mean, SD, range)	16.2 yrs (2.5) (13–20)	15.8 years (2.3) (12–21)	0.65
Study Medication dose (Mean, SD)	2.5 mg (1.2) (range 0.5 to 4 mg)	3.0 mg (1.0) (range 1.5 to 4 mg)	0.20
Time on study medication (Mean, SD)	8.6 weeks (4.2) (range 0 to 17 weeks) (9.6 ± 3.0 weeks for those 16 subjects in study >3 days)	9.3 weeks (3.2) (range 3 to 18 weeks)	0.52
LOC while on study medication (Mean days, SD)	Inpatient     17.3 (14.5)	Inpatient   15.1 (11.2)	0.62
	Day Treatment 23.8 (11.9)	Day Treatment   23.2 (11.1)	0.88
	Intensive Outpatient 26.4 (30.6)	Intensive Outpatient 15.8 (12.8)	0.54
	Outpatient    28.7 (18.1)	Outpatient    43.2 (25.5)	0.10
	Total      59.3 (21.7)	Total      63.6 (23.0)	0.61
% IBW at baseline	77.7% (4.7)	79.1% (3.8)	0.30
BMI at baseline	15.9 (1.0)	16.1 (1.3)	0.54
REE at baseline	1096 (183)	1070 (118)	0.60
EDI-2 DT at baseline	15.8 (4.6)	12.5 (7.8)	0.11
EDI-2 BD baseline	17.5 (6.7)	15.4 (9.8)	0.44
MASC-Total at baseline	62.9 (19.6)	61.5 (13.8)	0.80
CAPT-Total at baseline	3.7 (0.6)	3.4 (0.8)	0.21
BIS–PSE at baseline	9.3 (8.1)	9.2 (12.1)	0.99
BIS-DL at baseline	2.4 (0.9)	2.3 (0.7)	0.76
ADJ-current at baseline	11.4 (11.6)	10.9 (15.4)	0.90
ADJ-desired at baseline	−10.3 (9.3)	−4.4 (11.4)	0.24

Note: Group differences at baseline for mean age, medication dose, time on study medication, Level of Care (LOC), percent Ideal Body Weight (% IBW), Body Mass Index (BMI) and Resting Energy Expenditure (REE). Rating scales: Eating Disorder Inventory 2 (EDI-2); Drive for Thinness (EDI-2 DT) and Body Dissatisfaction (EDI-2 BD), Multidimensional Anxiety Scale for Children (MASC), Color-a-Person Test (CAPT), Body Image Software (BIS), Point of Subjective Equality (PSE), Difference Limens (DL), Adjustment-Current (ADJ-current) and Adjustment Desired (ADJ-desired)